Jupiter, Fla., October 8, 2015 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI) announced that Dyadic’s Chief Executive Officer Mark Emalfarb will make a presentation titled “There’s a saying that expression systems aren’t everything, but everything is nothing without a good expression system” at the 4th International Conference on Biologics and Biosimilars on Monday, October 26, 2015 at 4:30 p.m. ET at the DoubleTree by Hilton Hotel Baltimore – BWI Airport – Linthicum, Maryland.
This year’s Conference theme is “The future of next generation Biologics and Biosimilars”. Mr. Emalfarb will highlight Dyadic’s C1 expression system’s capabilities and its potential applications for use in developing and producing novel, and low cost vaccines, biosimilars and other biologics.
For registration information, please visit the conference website at http://biosimilars-biologics.pharmaceuticalconferences.com
Mr. Emalfarb will conduct one-on-one meetings throughout the conference dates of October 26 through 28, 2015. Attendees can contact Dyadic to arrange a meeting.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic’s ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic’s research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel, (6) Dyadic’s ability to obtain additional debt or equity financing sources and (7) other many other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in our December 31, 2014 Annual Report filed with OTC Markets on March 27, 2015.
Dyadic International, Inc.
Mark Emalfarb Chief Executive Officer